CAN008 prolongs overall survival in patients with newly diagnosed GBM characterized by high tumor mutational burden

Background: A previous phase 1 dose-escalation study in Taiwan indicated CAN008 (asunercept) with standard concurrent chemoradiotherapy (CCRT) improved progression-free survival (PFS) in newly diagnosed glioblastoma (GBM) patients. This study evaluates the efficacy of CAN008 in promoting overall sur...

Full description

Bibliographic Details

Published in:	Biomedical Journal
Main Authors:	Ian Yi-Feng Chang, Hong-Chieh Tsai, Chia-Hua Chen, Hsiu-Chi Chen, Chia-Wen Huang, Gerald F. Cox, Fang-Min Huang, You-Yu Lin, Ko-Ting Chen, Ya-Jui Lin, Kuo-Chen Wei
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Subjects:	Asunercept CAN008 GBM Tumor mutational burden Immunotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2319417023000975